Proactive One2One Healthcare Forum July 11th 2019 Clinigen Group Proactive One2One Healthcare Forum July 11th 2019

Introducing Clinigen – a UK Based global company A unique combination of businesses with an International platform

Introducing Clinigen – growth profile A strong track record of expansion through products, capabilities and infrastructure Adjusted gross profit Adjusted EBITDA Adjusted gross profit: 25% GROWTH VS H1 18 QUANTUM & IMMC ACQUIRED LINK ACQUIRED TOTECT ACQUIRED CSM & iQONE ACQUIRED PROLEUKIN US/RoW ACQUIRED IMUKIN ACQUIRED 46% CAGR GROWTH IN GROSS PROFIT 61% CAGR GROWTH IN EBITDA £80M SAVENE & ETHYOL ACQUIRED IDIS ACQUIRED CARDIOXANE ACQUIRED LIST ON AIM GROUP FORMED FOSCAVIR ACQUIRED PHASE 01 PHASE 02 PHASE 03 Consolidation of initial business, acquisition of additional assets Build infrastructure, development of global vision Global positioning, differentiation of businesses, genuine lifecycle partnership * Adjusted results exclude amortisation of acquired intangibles and products, and other non-underlying items relating to acquisitions. Adjusted EBITDA includes the Group’s share of EBITDA from its joint venture. Adjusted results include amortisation of software and internally developed IP. CAGR growth covers the eight year period between FY10 and FY18

Change in last 12 months CSM Increases size of customer base at early stage of product lifecycle. Additional capabilities that enhance propositions across all businesses. IQone Provides capability to support Clinigen and MA partner products. Growing a capability to commercialise products earlier in lifecycle. Proleukin and Imukin Acquisitions Niche, biologic products, limited risk of generic alternatives. Proleukin extensively used in clinical studies across the world. Creation of Clinigen Inc Commercial Medicines group. Launch of new online portal as part of overall Digital Strategy.

Proleukin Multiple revitalisation opportunities Regulatory Transitioning global Marketing Authorisations from Novartis to Clinigen, incl. US, EU and Row. Ability to manage unlicensed supply in other markets Manufacturing Development of new presentations and dosage forms of IL-2 Collaboration on multiple cell therapy manufacturing programs worldwide Clinical development New indication using low dose in Immunology (ALS, GVHD, LUPUS, Type I Diabetes, UC, MS, Transplant) High dose in Oncology (continued development of high dose IL-2 therapy in oncology) TIL and CAR-T Multiple revitalisation opportunities

EXTENDED GLOBAL FOOTPRINT UK: Burton-on-Trent Weybridge London Newcastle USA: Yardley | Malvern | Exton (PA) Fargo (ND) | Nashville (TN) HONG KONG SINGAPORE EUROPE: ireland SwitzerlanD Belgium Germany France greece INTERNATIONAL LOCATIONS 14 COUNTRIES SUPPLIED 108 UNITS SHIPPED 4.3M JAPAN SOUTH AFRICA AUSTRALIA NEW ZEALAND

THE INVESTMENT CASE UNIQUE COMBINATION OF BUSINESSES EXTENDING ACROSS PHARMA PRODUCT LIFECYCLE WITH CLEAR SYNERGIES MARKET-LEADING POSITIONS #1 IN CTS AND UNLICENSED MEDICINES SIGNIFICANT LONG-TERM GROWTH POTENTIAL BOTH ORGANIC AND ACQUISITIONAL GROWTH OPPORTUNITY HIGHLY CASH GENERATIVE WITH STRONG CREDIT CONTROL AND WORKING CAPITAL MANAGEMENT UNPARALLELED KNOWLEDGE AND EXPERTISE IN SUPPLY AND DISTRIBUTION OF UNLICENSED MEDICINES GLOBAL CAPABILITY SUPPLYING INTO OVER 100 COUNTRIES TRUSTED ETHICAL SUPPLIER DEEP RELATIONSHIPS WITH PHYSICIANS AND BIG PHARMA EXPERIENCED MANAGEMENT TEAM TRACK RECORD OF DELIVERING STRONG GROWTH

Right Medicine. Right Patient. Right Time Q&A Right Medicine. Right Patient. Right Time